HRP20130527T1 - Disubstituted phthalazine hedgehog pathway antagonists - Google Patents

Disubstituted phthalazine hedgehog pathway antagonists

Info

Publication number
HRP20130527T1
HRP20130527T1 HRP20130527AT HRP20130527T HRP20130527T1 HR P20130527 T1 HRP20130527 T1 HR P20130527T1 HR P20130527A T HRP20130527A T HR P20130527AT HR P20130527 T HRP20130527 T HR P20130527T HR P20130527 T1 HRP20130527 T1 HR P20130527T1
Authority
HR
Croatia
Prior art keywords
hedgehog pathway
pathway antagonists
disubstituted phthalazine
phthalazine hedgehog
disubstituted
Prior art date
Application number
HRP20130527AT
Other languages
Croatian (hr)
Inventor
Jolie Anne Bastian
Philip Arthur Hipskind
Daniel Jon Sall
Takako Wilson
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41566219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20130527(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20130527T1 publication Critical patent/HRP20130527T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20130527AT 2008-11-03 2013-06-12 Disubstituted phthalazine hedgehog pathway antagonists HRP20130527T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11070308P 2008-11-03 2008-11-03
PCT/US2009/061573 WO2010062507A1 (en) 2008-11-03 2009-10-22 Disubstituted phthalazine hedgehog pathway antagonists

Publications (1)

Publication Number Publication Date
HRP20130527T1 true HRP20130527T1 (en) 2013-07-31

Family

ID=41566219

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130527AT HRP20130527T1 (en) 2008-11-03 2013-06-12 Disubstituted phthalazine hedgehog pathway antagonists

Country Status (30)

Country Link
US (1) US8404687B2 (en)
EP (1) EP2364185B1 (en)
JP (1) JP2012507535A (en)
KR (1) KR101335746B1 (en)
CN (1) CN102202737B (en)
AU (1) AU2009320251C1 (en)
BR (1) BRPI0921437A2 (en)
CA (1) CA2742539C (en)
CL (1) CL2011000979A1 (en)
CO (1) CO6382123A2 (en)
CR (1) CR20110202A (en)
CY (1) CY1114023T1 (en)
DK (1) DK2364185T3 (en)
EA (1) EA018931B1 (en)
EC (1) ECSP11011021A (en)
ES (1) ES2418479T3 (en)
HK (1) HK1159010A1 (en)
HR (1) HRP20130527T1 (en)
IL (1) IL211841A0 (en)
MA (1) MA32726B1 (en)
MX (1) MX2011004683A (en)
NZ (1) NZ591945A (en)
PE (1) PE20110433A1 (en)
PL (1) PL2364185T3 (en)
PT (1) PT2364185E (en)
SI (1) SI2364185T1 (en)
TN (1) TN2011000166A1 (en)
UA (1) UA102115C2 (en)
WO (1) WO2010062507A1 (en)
ZA (1) ZA201102448B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA100684C2 (en) * 2007-03-15 2013-01-25 Новартіс Аг Normal;heading 1;heading 2;heading 3;BENZYL AND PYRIDINYL DERIVATIVES AS MODULATORS OF THE HEDGEHOG SIGNALING PATHWAY
NZ588001A (en) 2008-04-29 2012-06-29 Lilly Co Eli Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CN102216292B (en) 2008-11-17 2014-08-13 伊莱利利公司 Tetrasubstituted pyridazines HEDGEHOG pathway antagonists
PL2358698T3 (en) 2008-11-17 2013-01-31 Lilly Co Eli Tetrasubstituted pyridazine as hedgehog pathway antagonists
AR077014A1 (en) 2009-06-19 2011-07-27 Lilly Co Eli COMPOUND DERIVED FROM FTALAZINE 1,4-DISPOSED, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER
WO2015073691A1 (en) 2013-11-14 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of bmp signaling
CN105985319B (en) * 2015-02-11 2019-02-26 复旦大学 Aryl phthalazine compound and its preparation method and application
CN105985321B (en) * 2015-02-11 2018-10-26 复旦大学 Pyrazoles phthalazine compound and its preparation method and application
CN105985320B (en) * 2015-02-11 2018-10-26 复旦大学 Benzyl phthalazine compound and its preparation method and application
WO2024064245A1 (en) * 2022-09-23 2024-03-28 Merck Sharp & Dohme Llc Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
EP0876366B1 (en) 1996-01-15 2001-07-25 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
EP0882717B1 (en) * 1996-10-01 2010-09-08 Kyowa Hakko Kirin Co., Ltd. Nitrogenous heterocyclic compounds
EP1067939B1 (en) 1998-04-09 2015-09-16 The Johns Hopkins University Use of steroidal alkaloid derivatives as inhibitors of hedgehog protein signaling pathways
US6432970B2 (en) * 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
DE60016402T2 (en) 1999-06-08 2005-10-27 Lorantis Ltd. THERAPEUTIC USE OF AN INHIBITOR OF THE HEDGEHOG SIGNAL TRANSMISSION PATH
CA2483311A1 (en) 2002-04-22 2003-10-30 Philip A. Beachy Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (en) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation Fused pyridazine derivatives
AU2005260102A1 (en) 2004-05-08 2006-01-12 Novartis International Pharmaceutical Ltd. 3-aryl-5,6-disubstituted pyridazines
PL1789390T3 (en) * 2004-09-02 2012-04-30 Genentech Inc Pyridyl inhibitors of hedgehog signalling
EP1900731A1 (en) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amides as EP2-receptor modulators
UA100684C2 (en) 2007-03-15 2013-01-25 Новартіс Аг Normal;heading 1;heading 2;heading 3;BENZYL AND PYRIDINYL DERIVATIVES AS MODULATORS OF THE HEDGEHOG SIGNALING PATHWAY
US8153633B2 (en) * 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
WO2009035568A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
NZ588001A (en) * 2008-04-29 2012-06-29 Lilly Co Eli Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CN102216292B (en) 2008-11-17 2014-08-13 伊莱利利公司 Tetrasubstituted pyridazines HEDGEHOG pathway antagonists
PL2358698T3 (en) 2008-11-17 2013-01-31 Lilly Co Eli Tetrasubstituted pyridazine as hedgehog pathway antagonists
AR077014A1 (en) * 2009-06-19 2011-07-27 Lilly Co Eli COMPOUND DERIVED FROM FTALAZINE 1,4-DISPOSED, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER

Also Published As

Publication number Publication date
CN102202737B (en) 2014-03-26
TN2011000166A1 (en) 2012-12-17
NZ591945A (en) 2012-10-26
KR101335746B1 (en) 2013-12-12
ECSP11011021A (en) 2011-06-30
JP2012507535A (en) 2012-03-29
PT2364185E (en) 2013-07-24
AU2009320251A1 (en) 2010-06-03
MA32726B1 (en) 2011-10-02
PE20110433A1 (en) 2011-07-09
CY1114023T1 (en) 2016-07-27
CA2742539A1 (en) 2010-06-03
ES2418479T3 (en) 2013-08-14
EP2364185B1 (en) 2013-05-22
BRPI0921437A2 (en) 2018-10-30
US20110190304A1 (en) 2011-08-04
HK1159010A1 (en) 2012-07-27
MX2011004683A (en) 2011-06-20
US8404687B2 (en) 2013-03-26
ZA201102448B (en) 2012-09-26
EP2364185A1 (en) 2011-09-14
EA201170640A1 (en) 2011-12-30
CR20110202A (en) 2011-06-09
KR20110066212A (en) 2011-06-16
AU2009320251C1 (en) 2013-08-15
WO2010062507A1 (en) 2010-06-03
IL211841A0 (en) 2011-06-30
AU2009320251B2 (en) 2013-01-24
CA2742539C (en) 2014-05-06
DK2364185T3 (en) 2013-06-03
CO6382123A2 (en) 2012-02-15
PL2364185T3 (en) 2013-10-31
SI2364185T1 (en) 2013-07-31
UA102115C2 (en) 2013-06-10
CL2011000979A1 (en) 2011-10-07
EA018931B1 (en) 2013-11-29
CN102202737A (en) 2011-09-28

Similar Documents

Publication Publication Date Title
HRP20130408T1 (en) Disubstituted phthalazine hedgehog pathway antagonists
IL208211A0 (en) Disubstituted phthalazine hedgehog pathway antagonists
HRP20130527T1 (en) Disubstituted phthalazine hedgehog pathway antagonists
IL237392A0 (en) Pharmaceutical combination
EP2361340A4 (en) Packer
IL207378A0 (en) Pharmaceutical solid state forms
DK2301489T3 (en) Tredimensionelt ortopædisk udstyr til rygsøjlen
HK1152640A1 (en) Pharmaceutical combination
HU0800591D0 (en) Stable pharmaceutical combination
AU322206S (en) Monitor
HU0800414D0 (en) Pharmaceutical combination
GB0818712D0 (en) Therapeutic substances
GB0810952D0 (en) Therapeutic substances
GB0804377D0 (en) Therapeutic substances
GB0812816D0 (en) Therapeutic substances
GB0802576D0 (en) Dosage form
AU2008298V (en) Proquest D3 Dianella caerulea
GB0807453D0 (en) General problem solver
HU0800039V0 (en) Construction set
GB0819442D0 (en) Monitor
GB0805729D0 (en) K9 easybath